Accessibility settings

This paper is in the following e-collection/theme issue:

Viewpoints and Perspectives (9) Clinical Information and Decision Making (2149) Participatory Cancer Care (128) Clinical Cancer Research (139) Cancer and Clinical Trials (52) Patient-Reported Outcome Measures (PROMs) (397) Chemotherapy and Side Effects Management (128)

Published on in Vol 11 (2025)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/64611, first published .
Doctor reviews patient health questionnaire on tablet with patient

Leveraging Patient-Reported Outcome Measures for Optimal Dose Selection in Early Phase Cancer Trials

Leveraging Patient-Reported Outcome Measures for Optimal Dose Selection in Early Phase Cancer Trials

Authors of this article:

Bill Byrom1 Author Orcid Image ;   Anthony Everhart1 Author Orcid Image ;   Paul Cordero2 Author Orcid Image ;   Chris Garratt3 Author Orcid Image ;   Tim Meyer4 Author Orcid Image
Article Authors Cited by (2) Tweetations Metrics

Journals

  1. Mitchell S, Altshuler R, St. Germain D, Streck B, Chen A, Minasian L. Measuring the multidimensional aspects of tolerability. Cancer 2025;131(S2) View
  2. Daenen F, van Driessche A, Scherrens A, Janssens A, Rottey S, Decoster L, Stevens P, Pardon K, De Vleminck A, Beernaert K, BAYUO J. Integration of palliative care into phase I oncology trials: A qualitative interview study with patients, informal caregivers, and healthcare providers. PLOS One 2026;21(5):e0347349 View